pharma news today glp-1 A network meta-analysis backed weight-loss benefits with several receptor agonists, with less certainty for newer-generation agents. Read more at the link in bio Pills, TikTok and weight-loss apps:

Description

doi: 10.4236/fns.2016.711099

#DiabetesResearch Effectiveness and safety of combining SGLT2 inhibitors and GLP-1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of cohort studies - Diabetologia link.springer.com To view or add a comment, sign in More Relevant Posts Major milestone in diabetes-cardiovascular therapeutics The Rybelsus (oral semaglutide) tablets from Novo Nordisk have just received FDA approval to reduce the risk of major adverse cardiovascular events (MACE) including heart attack, stroke, or cardiovascular death in adults living with type 2 diabetes at elevated cardiovascular risk

The PIONEER 6 cardiovascular outcomes trial demonstrated that oral semaglutide was non-inferior to placebo for major adverse cardiovascular events (MACE) in high-risk patients

The glucagon-like peptide-1 receptor (GLP1R) is a crucial target in treating type 2 diabetes and obesity, given its significant role in regulating blood sugar levels and appetite